

Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials

Kazem Rahimi^{1,2,3*}, William Majoni⁴, Amal Merhi⁵, and Jonathan Emberson⁵

¹George Centre for Healthcare Innovation, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK; ²Department of Cardiovascular Medicine, University of Oxford, Oxford, UK; ³Department of Cardiology, Oxford University Hospitals, John Radcliffe Hospital, Oxford, UK; ⁴Department of Nephrology, Royal Darwin Hospital, Casuarina, Darwin, Northern Territory, Australia; and ⁵Clinical Trial Service and Epidemiological Studies Unit, University of Oxford, Oxford, UK

Received 30 September 2011; revised 14 December 2011; accepted 5 January 2012; online publish-ahead-of-print 3 February 2012

See page 1551 for the editorial comment on this article (doi:10.1093/eurheartj/ehs027)

Aims

The effect of statin treatment on ventricular arrhythmic complications is uncertain. We sought to test whether statins reduce the risk of ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death.

Methods and results

We searched MEDLINE, EMBASE, and CENTRAL up to October 2010. Randomized controlled trials comparing statin with no statin or comparing intensive vs. standard dose statin, with more than 100 participants and at least 6-month follow-up were considered for inclusion and relevant unpublished data obtained from the investigators. Twenty-nine trials of statin vs. control (113 568 participants) were included in the main analyses. In these trials, statin therapy did not significantly reduce the risk of ventricular tachyarrhythmia [212 vs. 209; odds ratio (OR) = 1.02, 95% confidence interval (CI) 0.84–1.25, $P = 0.87$] or of cardiac arrest (82 vs. 78; OR = 1.05, 95% CI 0.76–1.45, $P = 0.84$), but was associated with a significant 10% reduction in sudden cardiac death (1131 vs. 1252; OR = 0.90; 95% CI 0.82–0.97, $P = 0.01$). This compared with a 22% reduction in the risk of other ‘non-sudden’ (mostly atherosclerotic) cardiac deaths (1235 vs. 1553; OR = 0.78, 95% CI 0.71–0.87, $P < 0.001$). Results were not materially altered by inclusion of eight trials (involving 41 452 participants) of intensive vs. standard dose statin regimens.

Conclusion

Statin have a modest beneficial effect on sudden cardiac death. However, previous suggestions of a substantial protective effect on ventricular arrhythmic events could not be supported.

Keywords

Statin • Ventricular arrhythmia • Sudden death • Meta-analysis

Introduction

About half of all deaths due to heart disease manifest as sudden cardiac arrest or sudden cardiac death, many of which occur out of hospital before acute medical help can be reached.¹ While acute coronary events are the major underlying cause of sudden cardiac death, many of these are thought to be primarily caused by ventricular tachyarrhythmia.^{2–4} Despite the clear public health relevance of fatal arrhythmic events, strategies for their prediction and prevention remain challenging.⁵

During recent years, a number of observational studies have suggested that raised inflammatory markers are associated with a

higher future risk of ventricular tachyarrhythmia and sudden cardiac death in a variety of clinical settings.^{6–9} This, together with evidence indicating that statins reduce inflammation¹⁰ as well as experimental findings on other biological effects of statins unrelated to their LDL-cholesterol-lowering effects, has raised the hope that such treatment may, in addition to its undisputed anti-atherosclerotic effects, have some direct anti-arrhythmic effects.^{11–13} Potential pathophysiological mechanisms for such an effect may include plaque stabilisation, changes to the transmembrane ion channel conduction, anti-oxidant and anti-proliferative effects, and decrease in the parasympathetic tone.¹² Supportive evidence for such an anti-arrhythmic effect of statins comes from

* Corresponding author. Tel: +44 1865 617201, Fax: +44 1865 617202, Email: kazem.rahimi@georgecentre.ox.ac.uk

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2012. For permissions please email: journals.permissions@oup.com

a number of non-randomized studies^{14–17} and meta-analysis of such studies,¹⁸ showing an association between statin use and reduced risk of ventricular arrhythmic events. However, reliable evidence from randomized clinical trials is not available, partly because many large-scale statin trials have not published information on such events or were not individually sufficiently powered to test this hypothesis.⁵

To reach a more precise estimate of effects, we set out to perform a meta-analysis of all large-scale trials of a statin vs. a control, or of a more vs. a less intensive statin regimen, which have collected, but not necessarily published, data on ventricular arrhythmic events. In particular, we sought to estimate the effects separately on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death.

Methods

Search strategy for identification of relevant studies

Study methods have been published previously.¹⁹ In brief, we searched MEDLINE (January 1966 to October 2010), EMBASE (January 1985 to October 2010), and the Cochrane Central Register of Controlled Trials (up to October 2010) for articles with a subject term 'hydroxymethylglutaryl-coenzyme A reductase inhibitor' or any of the following terms: 'hydroxymethylglutaryl-co a reductase inhibitor', 'statin', 'fluvastatin', 'pravastatin', 'lovastatin', 'simvastatin', 'atorvastatin', or 'rosuvastatin'. The search was limited to randomized controlled trials with no language restrictions.

Review methods and selection criteria

Two reviewers independently screened all titles and abstracts for randomized controlled trials with either a parallel or factorial design, with at least one comparison of a statin vs. a control regimen or a more vs. less intensive statin regimen, and with 100 or more participants followed for at least 6 months. All such trials were considered potentially eligible; there were no restrictions placed on participant characteristics or study outcomes. We also hand-searched the reference lists of these studies to ensure that other relevant articles, such as meta-analyses of statin trials or other types of articles related to statins and cardiac arrhythmias, were not missed. After removing duplicate reports, full-text articles of all remaining reports were examined.

Data abstraction

An electronic data abstraction form was used to capture the following information: study name or investigator's name; recruitment period; mean follow-up duration; year of publication of the primary findings; randomized treatment comparisons; summary information about the studied population (number of participants, mean age, number of men, and prevalence of myocardial infarction or heart failure at randomization); the primary outcome of the study; the mean LDL-cholesterol level at randomization and at 1-year follow-up (or end of the study if follow-up duration was less than a year) by treatment allocation; and the number of patients with any of the following events: ventricular tachycardia or fibrillation (i.e. ventricular tachyarrhythmia), resuscitated cardiac arrest, sudden cardiac death, and all cardiac death. In trials where such events had not previously been reported, we asked the investigators to abstract the relevant numbers from their routine records of adverse events. We also asked the investigators to provide information about the definition

used for the outcomes of interest. However, since most of these outcomes had not been pre-specified or adjudicated, no unique definition could be provided. Non-responders were sent at least one reminder after about three weeks.

Assessment of risk of bias

To identify potential sources of bias in the reported events, we considered the following domains for each trial individually: (i) selection bias (random sequence generation and allocation concealment); (ii) performance bias (blinding of participants and study investigators for the outcomes of interest); (iii) detection bias (blinding of outcome assessors); (iv) attrition bias (incomplete outcome data); (v) reporting bias (selective outcome reporting). Risk of bias for each domain was categorized into low, unclear or high. This information was used to make judgements about the overall risk of bias for each study. We followed the Cochrane Collaboration's recommendation to make judgements based on whether the ranking of the level of bias across domains could have led to any material bias on the outcomes of interests and, if it could, what the direction of the bias would likely be.²⁰

Statistical analysis

To test the primary hypothesis that statins might reduce the risk of particular arrhythmic events, the main analyses were restricted to the trials of a statin vs. a control regimen (i.e. placebo or usual care). However, since the anti-inflammatory effect of statins—one of the key mechanisms for their potential anti-arrhythmic effects—have been suggested to be more pronounced in high-dose statin therapy,²¹ secondary analyses based on additional trials that had compared a more intensive vs. a standard statin regimen were also performed.

For each trial, the 'observed minus expected' statistic ($o - e$) and its variance (v) were calculated from the number of patients who developed each arrhythmic event and the total number of patients in each treatment group. These ($o - e$) values, one from every trial, were summed to produce a grand total (G), with variance (V) equal to the sum of their separate variances. The value $\exp(G/V)$ is Peto's 'one-step' estimate of the odds ratio (OR) and its continuity corrected 95% confidence interval (CI) is given by $\exp(G/V \pm [0.5/V + 1.96/\sqrt{V}])$.²² Heterogeneity between the individual trials was assessed by calculating $S - G^2/V$, where S is the sum of $[o - e]^2/v$ for each trial, and testing this statistic against a χ^2 distribution with degrees of freedom equal to one less than the number of trials. Tests for trend in the magnitude of the log OR when trials were ordered by their statistic size (i.e. v) were also performed.

To test whether there was a differential effect of statins on sudden cardiac death compared with other 'non-sudden' cardiac death, we estimated the effects on each separately (in the trials in which both outcomes were reported), comparing the two estimates using a standard χ^2 test on 1 degree of freedom.

The difference in LDL cholesterol achieved between randomized groups in the trials of a more intensive vs. a standard dose statin regimen was typically much lower than that achieved in the trials of statin vs. control. If the magnitude of any true relative risk reduction was related to this difference, a standard meta-analysis of the results in the different trials could be misleading. Therefore, in addition to the main analyses, supplementary 'LDL-weighted' analyses were also performed to provide the estimate of the OR per 1.0 mmol/L reduction in LDL cholesterol.

Results

Figure 1 summarizes the search retrieval process. Out of 4034 abstracts reviewed, 219 papers describing 102 trials were retrieved

for further examination, of which 83 met the inclusion criteria. Of these, 37 trials were included in the analysis (most of the others reported that such events were not recorded in the trial). Twenty-nine trials (including 113 568 randomized participants and




Table 1 Summary of trials' characteristics

Study	Year of publication of main results	Mean follow-up (years)	Country/region	Treatment comparison		LDL-c difference ^a (mmol/L)	Population characteristics				
				Intervention	Control regimen		Main inclusion criteria	Total number of participants	Mean age (years)	Male (%)	Prior MI (%)
Statin vs. control regimen											
PMSG-CR ²³	1993	0.5	Multinational	P 20–40 mg	Placebo	1.22	MI, angina or other risk factors	1062	55	77	34
4S ²⁴	1994	5.2	Nordics	S 40 mg	Placebo	1.77	MI or angina	4444	58	81	79
MAAS ²⁵	1994	4.0	Europe	S 20 mg	Placebo	1.40	Confirmed CHD plus other risk factors	381	56	88	55
PLAC-1 ²⁶	1995	2.3	USA	P 40 mg	Placebo	1.22	Confirmed CHD	408	57	78	44
PREDICT ²⁷	1997	0.5	France	A 10 mg	Placebo	1.03	Post PCI	695	58	83	37
AFCAPS/ TexCAPS ²⁸	1998	5.3	USA	L 20–40 mg	Placebo	0.94	Primary prevention	6605	58	85	0
LIPID ²⁹	1998	5.6	Australia, New Zealand	P 40 mg	Placebo	1.03	History of MI or UA	9014	62	83	64
GISSI-P ³⁰	2000	1.9	Italy	P 20–40 mg	No treatment	0.35	Recent MI	4271	60	86	100
HPS ³¹	2002	5.0	UK	S 40 mg	Placebo	1.29	Vascular disease or diabetes	20 536	64	75	41
LIPS ³²	2002	3.1	Europe, Canada, Brazil	F 80 mg	Placebo	0.92	Post PCI	1677	60	84	44
FLORIDA ³³	2002	1.0	USA	F 40 mg	Placebo	1.20	MI	540	61	83	100
ASCOT-LLA ³⁴	2003	3.2	Nordics and UK	A 10 mg	Placebo	1.07	Hypertension plus other risk factor	10 305	65	81	0
ALERT ³⁵	2003	5.1	Multinational	F 40 mg	Placebo	0.84	Renal transplant recipients	2102	50	66	34
CARDS ³⁶	2004	3.9	UK, Ireland	A 10 mg	Placebo	1.14	Type 2 diabetes plus other risk factor	2838	62	68	0
PREVEND IT ³⁷	2004	3.8	Netherlands	P 40 mg	Placebo	1.00	Microalbuminuric patients	864	51	65	0
ALLIANCE ³⁸	2004	4.3	USA	A 10–80 mg	Usual care	1.16	CHD	2442	61	82	58
PCAB ³⁹	2005	4.5	Japan	P 10–20 mg	Usual care	0.49	After CABG	335	59	85	62
4D ⁴⁰	2005	3.9	Germany	A 20 mg	Placebo	0.89	Diabetic haemodialysis patients	1255	66	54	18
NEDIAT ⁴¹	2005	2.9	Sweden	A 10 mg	Placebo	0.71	CKD Stages 4 and 5	143	70	69	24
MEGA ⁴²	2006	5.3	Japan	P 10–20 mg	No treatment	0.67	Primary prevention	7832	58	30	0
ASPEN ⁴³	2006	4.3	Multinational	A 10 mg	Placebo	0.99	Type 2 diabetes	1864	61	66	17
SPARCL ⁴⁴	2006	4.9	Multinational	A 80 mg	Placebo	1.43	Stroke or TIA, no CHD	4731	63	60	0
CLARIDI ⁴⁵	2006	1.0	Belgium, Greece	A 80 mg	Placebo	1.68	CHD with internal cardioverter defibrillator	106	67	94	87

CORONA ⁴⁶	2007	2.7	Multinational	R 10 mg	Placebo	1.61	Ischemic heart failure	5011	73	76	60
JUPITER ⁴⁷	2008	1.9	Multinational	R 20 mg	Placebo	1.09	Primary prevention	17 802	66	62	0
GISSI-HF ⁴⁸	2008	3.9	Italy	R 10 mg	Placebo	0.92	CHF	4574	68	77	32
Vrtovec <i>et al.</i> ⁴⁹	2008	1.0	Slovenia	A 10 mg	Usual care	1.91	CHF	110	63	61	59
METEOR ⁵⁰	2009	2.0	Multinational	R 40 mg	Placebo	1.79	Primary prevention	981	60	57	60
LEADe ⁵¹	2010	1.5	Multinational	A 80 mg	Placebo	0.30	Mild-to-moderate probable Alzheimer disease	640	74	48	0
<hr/>											
More vs. less intensive statin therapy											
A-Z ⁵²	2004	2.0	Multinational	S 80 mg	S 20 mg	0.30	Acute coronary syndrome	4497	61	75	17
REVERSAL ⁵³	2004	1.5	USA	A 80 mg	P 40 mg	0.97	>20% stenosis on routine coronary angiogram	657	56	72	0
PROVE IT ⁵⁴	2004	2.0	Multinational	A 80 mg	P 40 mg	0.65	Acute coronary syndrome	4162	58	78	18
TNT ⁵⁵	2005	4.9	Multinational	A 80 mg	A 10 mg	0.62	Clinically evident CHD	10 001	61	81	58
IDEAL ⁵⁶	2005	4.8	Nordics, Netherlands, Iceland	A 80 mg	S 20 mg	0.55	MI	8888	62	81	100
SAGE ⁵⁷	2007	1.0	Multinational	A 80 mg	P 40 mg	0.78	Elderly with CHD and evidence of ischaemia	893	72	69	46
Colivicchi <i>et al.</i> ⁵⁸	2010	0.7	Italy	A 80 mg	A 20–40 mg	0.80	Acute presentation of severe CHD	290	75	49	100
SEARCH ⁵⁹	2010	6.7	UK	S 80 mg	S 20 mg	0.39	Previous MI	12 064	64	83	100

MI, myocardial infarction; CHD, coronary heart disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; CKD, chronic kidney disease; TIA, transient ischaemic attack; CHF, chronic heart failure; SCD, sudden cardiac death; CA, cardiac arrest; VA, ventricular arrhythmia; UA, unstable angina; A, atorvastatin; L, lovastatin; P, pravastatin; R, rosuvastatin; S, simvastatin.

^aLDL-cholesterol differences are based on average differences between the two groups at 1 year (or the closest time to 1 year if 1 year data unavailable).

Table 2 Risk of bias for reported events of sudden death, cardiac arrest, and ventricular tachyarrhythmia

	Outcome available in the published literature			Selection bias	Performance bias	Detection bias	Attrition bias		Intention-to-treat analysis	Reporting bias	Overall risk of bias
	SCD	CA	VT				Description of withdrawals and losses to follow-up	Overall risk of attrition bias			
Statin vs. control regimen											
PMSG-CR ²³	Yes	—	—	Unclear	Low	Low	Yes	Low	Yes	Low	Low
4S ²⁴	Yes	Yes	—	Unclear	Low	Low	Yes	Low	Yes	Low	Low
MAAS ²⁵	Yes	—	—	Low	Low	Low	No	Low	Yes	Low	Low
PLAC-1 ²⁶	Yes	Yes	—	Unclear	Low	Low	Yes	Low	Yes	Low	Low
PREDICT ²⁷	Yes	—	—	Low	Low	Low	Yes	Low	Yes	Low	Low
AFCAPS/ TexCAPS ²⁸	Yes	—	—	Low	Low	Low	Yes	Low	Yes	Low	Low
LIPID ²⁹	Yes	—	—	Low	Low	Low	Yes	Low	Yes	Low	Low
GISSI-P ³⁰	Yes	—	No	Unclear	Low	Low	Yes	Low	Yes	Low	Low
HPS ³¹	Yes	No	No	Low	Low	Low	Yes	Low	Yes	Low	Low
LIPS ³²	Yes	—	—	Low	Low	Low	Yes	Low	Yes	Low	Low
FLORIDA ³³	Yes	—	—	Unclear	Low	Low	Yes	Low	Yes	Low	Low
ASCOT-LLA ³⁴	—	—	Yes	Low	Low	Low	Yes	Low	Yes	Low	Low
ALERT ³⁵	No	—	—	Low	Low	Low	Yes	Low	Yes	Low	Low
CARDS ³⁶	Yes	—	—	Low	Low	Low	Yes	Low	Yes	Low	Low
PREVEND IT ³⁷	No	—	—	Low	Low	Low	No	Low	Yes	Low	Low
ALLIANCE ³⁸	No	Yes	No	Unclear	Low	Low	Yes	Low	Yes	Low	Low
PCAB ³⁹	Yes	—	No	Low	Low	Low	Yes	Low	Yes	Low	Low
4D ⁴⁰	Yes	—	No	Low	Low	Low	Yes	Low	Yes	Low	Low
NEDIAT ⁴¹	No	—	—	Low	Low	Low	Yes	Low	Yes	Low	Low
MEGA ⁴²	Yes	—	No	Low	Low	Low	Yes	Low	Yes	Low	Low
ASPEN ⁴³	No	No	No	Low	Low	Low	Yes	Low	Yes	Low	Low
SPARCL ⁴⁴	—	Yes	—	Low	Low	Low	Yes	Low	Yes	Low	Low
CLARIDI ⁴⁵	—	—	Yes	Unclear	Low	Low	No	Low	Yes	Low	Unclear
CORONA ⁴⁶	Yes	Yes	Yes	Low	Low	Low	Yes	Low	Yes	Low	Low
JUPITER ⁴⁷	No	—	—	Low	Low	Low	Yes	Low	Yes	Low	Low
GISSI-HF ⁴⁸	Yes	—	Yes	Low	Low	Low	Yes	Low	Yes	Low	Low
Vrtovec et al. ⁴⁹	Yes	—	—	Unclear	Low	Low	No	Unclear	Yes	Low	Unclear
METEOR ⁵⁰	—	—	No	Low	Low	Low	Yes	Low	Yes	Low	Low
LEADe ⁵¹	Yes	—	No	Low	Low	Low	Yes	Low	Yes	Low	Low

More vs. less intensive statin therapy									
A-Z ⁵²	Yes	—	Low	Low	Yes	Low	Low	Yes	Low
REVERSAL ⁵³	—	No	Low	Low	Yes	Low	Low	Yes	Low
PROVE IT ⁵⁴	Yes	No	Low	Low	Yes	Low	Low	Yes	Low
TNT ⁵⁵	No	Yes	Unclear	Low	Yes	Low	Low	Yes	Low
IDEAL ⁵⁶	No	Yes	Low	Low	Yes	Low	Low	Yes	Low
SAGE ⁵⁷	—	Yes	Low	Low	Yes	Low	Low	Yes	Low
Colivicchi et al. ⁵⁸	No	—	Unclear	Low	Yes	Low	Low	Yes	Low
SEARCH ⁵⁹	—	No	Low	Low	Yes	Low	Low	Yes	Low

Selection bias is based on random sequence generation and allocation concealment; performance bias includes blinding of participants and study investigators for the outcomes of interest; detection bias includes blinding of outcome assessors; attrition bias includes the possibility of incomplete outcome data; and reporting bias includes the possibility of selective outcome reporting. Selection bias is a feature of the trial design. Performance and detection bias are overall low, given that most data were collected without any prior knowledge of the investigators of the tested hypothesis in this study at the time of event collection. All analyses in this report are based on intention-to-treat and we further mitigated the possible effect of any attrition bias and reporting bias at individual trial level by collection of additional unpublished data. SCD, sudden cardiac death; CA, cardiac arrest; VT, ventricular tachyarrhythmia.

~445 000 person-years of follow-up) compared statin vs. control^{23–51} and eight trials (including 41 452 randomized participants and ~192 000 person-years of follow-up) compared more vs. less intensive LDL lowering with statins (Table 1).^{52–59} Twelve of the included trials had not published information on ventricular arrhythmic events previously (eight trials of statin vs. control^{35,37,38,41,43,47,50,51} and five trials of more vs. less intensive statin therapy),^{53,55,56,58,59} and for another seven of the included trials, information from the published literature was complemented by additional unpublished data obtained from the investigators (six statin vs. control^{30,31,36,39,40,42} and one more intensive vs. standard dose statin trials).⁵⁴ One study was available only as a conference proceeding.⁴⁵ The average achieved 1-year difference in mean LDL cholesterol between randomized treatment arms was 1.13 mmol/L for the trials of statin vs. control and 0.53 mmol/L for the trials that compared a high dose of a statin with a standard dose. The risk of bias was judged to be unclear for two trials and low for all other trials (Table 2).

Ventricular tachyarrhythmia

Only two trials had previously published information on ventricular tachyarrhythmia^{34,46} with another two having presented such findings at a scientific meeting.^{45,48} Unpublished information on ventricular tachyarrhythmia was provided from investigators for an additional 14 trials.^{30,31,38–40,42,43,50,51,53–56,59} Overall, these 18 trials reported 672 patients with at least one episode of ventricular tachyarrhythmia. In the primary analysis of 13 statin vs. control trials, statin therapy did not reduce the risk of ventricular tachyarrhythmia significantly (212 vs. 209; OR = 1.02, 95% CI 0.84–1.25, *P* = 0.87; Figure 2). This result was not materially affected when all trials were considered together (OR = 1.06; 95% CI 0.91–1.24; *P* = 0.48; Figure 2). There was no significant heterogeneity within the trials of statin vs. control (and no good evidence of heterogeneity within the trials of more vs. less intensive therapy), no evidence of trend according to the study size, and no evidence that the effect sizes differed significantly between the two types of trials.

Cardiac arrest

Twelve trials reported a total of 254 cardiac arrests^{24,26,31,38,43,44,46,53–57} (eight of these trials had previously published such information).^{24,26,38,44,46,55–57} In the seven statin vs. control trials for which cardiac arrest data were available, statin therapy did not reduce the risk of cardiac arrest significantly (82 statin vs. 78 control, OR = 1.05; 95% CI 0.76–1.45; *P* = 0.84; Figure 3), although the CI was wide due to the relatively few numbers of events. Including the additional five trials of intensive vs. standard dose had little effect on the estimated effect size (overall OR = 0.98; 95% CI 0.76–1.27; *P* = 0.92; Figure 3). There was no evidence that the effect sizes differed significantly within either type of trial or between the two types of trials, and no evidence of trend according to study size.

Sudden cardiac death

Thirty trials reported a total of 2874 sudden cardiac deaths (nine trials had not previously published such information).^{35,37,38,41,43,47,55,56,58} In the 25 statin vs. control trials for




Figure 2 Effect of statin therapy on ventricular tachyarrhythmia.

which data were available, statin therapy was associated with a significant 10% proportional reduction in the risk of sudden cardiac death (1131 vs. 1252; OR = 0.90; 95% CI 0.82–0.97, $P = 0.01$) with no good evidence of heterogeneity between the trials ($P = 0.09$; Figure 4). Including the additional five trials of intensive vs. standard dose had little effect on the size of the estimated OR (overall OR = 0.89; 95% CI 0.82–0.96; $P = 0.002$; Figure 4). There was no evidence that the proportional risk reduction differed significantly between the two types of trial. In the trials of statin vs. control, there was some evidence of trend ($P = 0.01$) towards apparently larger proportional risk reductions among the smaller trials, driven by an apparent lack of benefit in two large trials of patients with heart failure, which had also failed to show any overall effect on cardiovascular outcomes.^{46,48}

Of the 25 trials of statin vs. control that provided data on sudden cardiac death, 24 also provided data on all cardiac death, and hence, the numbers of patients having other (i.e. non-sudden)

cardiac death could be calculated. Compared with the 10% proportional reduction in sudden cardiac death seen in these 24 trials (1115 vs. 1227; OR = 0.90, 99% CI 0.81–1.01, $P = 0.02$), there was a significant 22% proportional reduction in the risk of other ‘non-sudden’ cardiac death (1235 vs. 1553; OR = 0.78 99% CI 0.71–0.87; $P < 0.001$; P -value for difference in effect size between the two outcomes = 0.02; Figure 5). Consequently, statin therapy was associated with a significant 17% proportional reduction in the risk of all cardiac death (2350 vs. 2780; OR = 0.83, 95% CI 0.78–0.88; $P < 0.001$; Figure 5). Inclusion of the additional more vs. less intensive statin therapy trials did not materially affect the size of the estimated ORs for other non-sudden cardiac death (29 trials, 1408 vs. 1754; OR = 0.79; 95% CI 0.74–0.85; $P < 0.001$).

Adjusting the effect seen in each trial for the LDL-cholesterol difference achieved in each trial⁶⁰ had no notable impact on any of the findings (results available on request).




Figure 3 Effect of statin therapy on cardiac arrest.

Discussion

This study is the most comprehensive meta-analysis of the effect of statin therapy on ventricular arrhythmic events collecting both published and unpublished information from a large set of randomized controlled trials. While we found no evidence that statin therapy significantly reduced the risk of ventricular tachyarrhythmia or of cardiac arrest, the risk of sudden cardiac death was reduced by 10% compared with a reduction in the risk of other (non-sudden) cardiac deaths of about 20%.

Are these findings compatible with a direct anti-arrhythmic effect of statins? Sudden cardiac death is a clinical syndrome that can be caused either *primarily* by arrhythmia, i.e. a primary electrical event, or by acute coronary events *complicated* by arrhythmia.^{3,4} In clinical studies, it is difficult to distinguish between the two causative mechanisms (and some non-cardiac events may in fact have been misclassified as sudden cardiac death). However, autopsy studies suggest that in the general population, at least a third of people diagnosed with sudden cardiac death will have evidence of acute coronary occlusion with a further third showing evidence of plaque erosion.^{2,61–63} Since statins reduce the risk of acute coronary events, one might expect a reduction in sudden cardiac death due solely to effects on lipid-lowering. It is

unclear what magnitude risk reduction this might translate to however and, consequently, we cannot exclude the possibility of some direct anti-arrhythmic effect of statins existing. However, the observation that the reduction in risk of sudden cardiac death was only half of that for other (mostly atherosclerotic) cardiac death, together with the lack of evidence for any effect on ventricular tachyarrhythmia, does not lend much support to any clinically relevant direct ventricular anti-arrhythmic benefit.

Our findings contrast with the previous suggestion that statins reduce the risk of ventricular tachyarrhythmia by about one-third.^{14–18,45} This could be due to residual confounding and other inherent biases in the previous non-randomized studies^{14–18} together with large random errors in the one small randomized controlled trial to have directly tested this hypothesis.⁴⁵ Similarly, in a previous meta-analysis of randomized controlled trials of 10 trials and only 750 events, it was estimated that statins reduce the risk of sudden cardiac death by about one-fifth.⁶⁴ However, that meta-analysis included only published results and in total included only about one-third as many sudden cardiac deaths as the current study (which also sought to include unpublished data, thereby avoiding the biases that can be introduced by the favourable publication of apparently promising findings).^{65,66}




Figure 4 Effect of statin therapy on sudden cardiac death.

Study limitations

Most non-fatal arrhythmic events reported in the various included trials were collected from adverse event forms and had not undergone the same rigorous evaluation as in published reports and not based on a unified definition. Although such procedures may have

resulted in underestimation of the true number of events and introduced some random errors, they are unlikely to have introduced any bias because underreporting and lack of independent confirmation of the events would be expected to have affected both study groups equally.^{19,67,68} Nevertheless, the relatively limited number




Figure 5 Effect of statin therapy on sudden cardiac death compared with other (non-sudden) cardiac death.

of cardiac arrests and ventricular tachyarrhythmia in the current report, in addition to any random errors resulting from the lack of a unified definition, means that a small benefit (or harm) of statins on these outcomes cannot be ruled out. Further evidence from adequately powered randomized controlled trials would therefore be needed to demonstrate whether any true benefits may exist.

Conclusions

Reducing LDL cholesterol with a statin reduces the risk of sudden cardiac death but the proportional benefit is small compared with that seen for other fatal cardiac events and may be explained by 'upstream' anti-atherosclerotic lipid-lowering effects. By contrast, there is no direct evidence that statins significantly reduce the risk of ventricular tachyarrhythmia.

Acknowledgements

We are grateful to the following people for their support and provision of unpublished data: 4D: Vera Krane, Christoph Wanner; ALERT: Hallvard Holdaas; ALLIANCE: Michael Koren; ASPEN: Robert Knopp; CARDS: Executive committee: Helen Colhoun, D. John Betteridge, Paul Durrington, John H. Fuller, Graham Hitman, Andrew Neil; study statistician: Shona Livingstone; study funders: Pfizer, NHS, and Diabetes UK; CLARIDI: Johan De Sutter; GISSI-P: Roberto Marchioli; Furio Colivicchi; HPS and SEARCH: Rory Collins, Jane Armitage; IDEAL: Terje Pederson; JUPITER: Paul Ridker; LEADE: Howard Feldman; MEGA: Haruo Nakamura, Shinji Hirosaki; METEOR: Michiel L. Bots; NEDIAT: Bernd Stegmayr; PCAB: Haruo Makuuchi; Pfizer: David Demicco, Luz Cubillos, Rana Fayyad; PREVENT-IT: Folkert Asselbergs; PROVE-IT: Chris Cannon, Sabina A. Murphy, Sara Sloan; REVERSAL: Steven E. Nissen; TNT: John LaRosa; and Paul McGale (data extraction).

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. KR is supported by a senior fellowship from the Oxford Martin School. J.E. acknowledges support from the British Heart Foundation Centre of Research Excellence, Oxford (RE 08/04). K.R. and J.E. had full access to all of the data

in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of interest: none declared.

References

- Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the united states, 1989 to 1998. *Circulation* 2001;**104**:2158–2163.
- Davies MJ, Bland JM, Hangartner JRV, Angelina A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. *Eur Heart J* 1989;**10**:203–208.
- Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: acute ischemia vs. myocardial substrate. *Circulation* 1997;**96**:3215–3223.
- Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. *J Cardiovasc Electrophysiol* 2001;**12**:369–381.
- Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Eur Heart J* 2006;**27**:2099–2140.
- Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of c-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation* 2002;**105**:2595–2599.
- Rahimi K, Watzlawek S, Thiele H, Secknus MA, Hayerizadeh BF, Niebauer J, Schuler G. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. *Eur Heart J* 2006;**27**:1706–1711.
- Blangy H, Sadoul N, Dousset B, Radauceanu A, Fay R, Aliot E, Zannad F. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. *Europace* 2007;**9**:724–729.
- Biasucci LM, Giubilo G, Biondi-Zoccai G, Sanna T, Liuzzo G, Piro M, De Martino G, Ierardi C, dello Russo A, Pelargonio G, Bellocchi F, Crea F. C reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillator. *Heart* 2006;**92**:1147–1148.
- Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. *J Am Med Assoc* 2001;**286**:64–70.
- Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. *J Cardiovasc Electrophysiol* 2003;**14**:S87–S95.
- Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? *Cardiovasc Res* 2007;**75**:10–20.

13. Tamargo J, Caballero R, Gomez R, Nunez L, Vaquero M, Delpon E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. *Pharmacol Ther* 2007;**114**:107–126.
14. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. *J Am Coll Cardiol* 2000;**36**:766–772.
15. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. *Am J Cardiol* 2005;**96**:611–616.
16. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, Zareba W, Steinberg JS, Fischer A, Ruskin J, Andrews ML. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. *J Am Coll Cardiol* 2006;**47**:769–773.
17. Goldberger JJ, Subacius H, Schaechter A, Howard A, Berger R, Shalaby A, Levine J, Kadish AH. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. *J Am Coll Cardiol* 2006;**48**:1228–1233.
18. Wanahita N, Chen J, Bangalore S, Shah K, Rachko M, Coleman CI, Schweitzer P. The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis. *Am J Ther* 2010; doi:10.1097/MJT.1090b1013e3181e9087a
19. Rahimi K, Emberson J, McGale P, Majoni W, Merhi M, Asselbergs FW, Krane V, Macfarlane PV. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. *Br Med J* 2011;**342**:d1250.
20. Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org.
21. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. *Am J Cardiol* 2005;**96**:61f–68f.
22. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis* 1985;**27**:335–371.
23. Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M. A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin multinational study group for diabetes. *Clin Cardiol* 1994;**17**:558–562.
24. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;**344**:1383–1389.
25. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). *Lancet* 1994;**344**:633–638.
26. Pitt B, John Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. *J Am Coll Cardiol* 1995;**26**:1133–1139.
27. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, Bassand JP, Machecourt J, Cassagnes J, Mossard JM, Vacheron A, Castaigne A, Danchin N, Lablanche JM. Effect of pravastatin on angiographic stenosis after coronary balloon angioplasty. *J Am Coll Cardiol* 1997;**30**:863–869.
28. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *J Am Med Assoc* 1998;**279**:1615–1622.
29. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998;**339**:1349–1357.
30. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per Lo Studio della Sopravvivenza nell'Infarto Miocardico). *Ital Heart J* 2000;**1**:810–820.
31. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [isrctn48489393]. *BMC Med* 2005;**3**:6.
32. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *J Am Med Assoc* 2002;**287**:3215–3222.
33. Liem AH, Van Boven AJ, Veeger NJGM, Withagen AJ, Robles de Medina RM, Tijssens JGP, Van Veldhuisen DJ. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. *Eur Heart J* 2002;**23**:1931–1937.
34. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003;**361**:1149–1158.
35. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 2003;**361**:2024–2031.
36. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. *Lancet* 2004;**364**:685–696.
37. Asselbergs FW, Diercks GFH, Hillege HL, Van Boven AJ, Janssen WMT, Voors AA, De Zeeuw D, De Jong PE, Van Veldhuisen DJ, Van Gilst WH. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. *Circulation* 2004;**110**:2809–2816.
38. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. *J Am Coll Cardiol* 2004;**44**:1772–1779.
39. Makuuchi H, Furuse A, Endo M, Nakamura H, Daida H, Watanabe M, Ohashi Y, Hosoda Y, Hosoda S, Yamaguchi H, Yasui H. Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery—pravastatin coronary artery bypass graft study. *Circ J* 2005;**69**:636–643.
40. Wanner C, Krane V, Marz W, Olschewski M, Mann JFE, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005;**353**:238–248.
41. Stegmayr BG, Brannstrom M, Bucht S, Crougneau V, Dimeny E, Ekspong A, Eriksson M, Granroth B, Grontoft KC, Hadimeri H, Holmberg B, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Stenlund H, Wikdahl AM. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. *Scand J Urol Nephrol* 2005;**39**:489–497.
42. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. *Lancet* 2006;**368**:1155–1163.
43. Knopp RH, D'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care* 2006;**29**:1478–1485.
44. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Silleisen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;**355**:549–559.
45. De Sutter J, De Bacquer D, Jordaens L, De Buyzere M, Matthys K, De Backer G, Tavernier R. Intensive lipid-lowering therapy and ventricular arrhythmias in patients with coronary artery disease and internal cardioverter defibrillators. Heart Rhythm Society 2006 Scientific Sessions 2006.
46. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaefelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;**357**:2248–2261.
47. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;**359**:2195–2207.
48. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;**372**:1231–1239.
49. Vrtovc B, Okrajsek R, Golcink A, Ferjan M, Starc V, Schlegel TT, Radovancevic B. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. *J Cardiac Fail* 2008;**14**:140–144.
50. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. *J Am Med Assoc* 2007;**297**:1344–1353.
51. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADE. *Neurology* 2010;**74**:956–964.

52. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *J Am Med Assoc* 2004;**292**:1307–1316.
53. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *J Am Med Assoc* 2004;**291**:1071–1080.
54. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive vs. moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;**350**:1495–1504.
55. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;**352**:1425–1435.
56. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *J Am Med Assoc* 2005;**294**:2437–2445.
57. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, Piotrowicz R, Schenck-Gustafsson K, Sellier P, Stein JH, Thompson PL, Tzivoni D. Effects of intensive vs. moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). *Circulation* 2007;**115**:700–707.
58. Colivicchi F, Tubaro M, Mocini D, Genovesi Ebert A, Strano S, Melina G, Uguccioni M, Santini M. Full-dose atorvastatin vs. conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. *Curr Med Res Opin* 2010;**26**:1277–1284.
59. Search collaborative group. Intensive lowering of LDL cholesterol with 80 mg vs. 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet* 2010;**376**:1658–1669.
60. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;**366**:1267–1278.
61. Taylor AJ, Burke AP, O'Malley PG, Farb A, Malcom GT, Smialek J, Virmani R. A comparison of the Framingham risk index, coronary artery calcification, and culprit plaque morphology in sudden cardiac death. *Circulation* 2000;**101**:1243–1248.
62. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. *Circulation* 1995;**92**:1701–1709.
63. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R. Elevated c-reactive protein values and atherosclerosis in sudden coronary death. *Circulation* 2002;**105**:2019–2023.
64. Levantesi G, Scarano M, Marfisi R, Borrelli G, Rutjes AWS, Silletta MG, Tognoni G, Marchioli R. Meta-analysis of effect of statin treatment on risk of sudden death. *Am J Cardiol* 2007;**100**:1644–1650.
65. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. *N Engl J Med* 1997;**337**:536–542.
66. Ioannidis JPA. Why most published research findings are false. *PLoS Med* 2005;**2**:e124.
67. Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, Neal B, Reidies H, Santarelli L, Schroyer R, Stockbridge NL, Feng Z. Do we need to adjudicate major clinical events? *Clinical Trials* 2008;**5**:56–60.
68. Pogue J, Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. *Clinical Trials* 2009;**6**:239–251.